$307 Million is the total value of JOHNSON & JOHNSON's 23 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 13.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LEGN | Legend Biotech Corporationads | $78,558,722 | +96494.9% | 1,629,173 | 0.0% | 25.55% | +8.0% | |
| PTGX | Protagonist Therapeutics Inc. | $56,331,209 | +210712.5% | 2,449,183 | 0.0% | 18.32% | +135.7% | |
| MGTX | MeiraGTx Holdings plc | $34,334,301 | +79194.0% | 6,641,064 | 0.0% | 11.17% | -11.4% | |
| CVRX | CVRx, Inc. | $32,578,759 | +50690.0% | 3,495,575 | 0.0% | 10.60% | -43.2% | |
| XNCR | Xencor, Inc. | $20,863,449 | +107001.9% | 748,062 | 0.0% | 6.79% | +19.7% | |
| FATE | Fate Therapeutics, Inc. | $19,260,665 | +56391.2% | 3,379,064 | 0.0% | 6.26% | -36.8% | |
| FUSN | Fusion Pharmaceuticals Inc. | $13,837,845 | +119583.8% | 3,670,516 | 0.0% | 4.50% | +33.8% | |
| Procept BioRobotics Corporation | $10,165,468 | +68266.9% | 357,939 | 0.0% | 3.31% | -23.6% | ||
| Cue Health, Inc. | $10,098,932 | +87823.8% | 5,548,864 | 0.0% | 3.28% | -1.7% | ||
| PNT | Point Biopharma Global Inc. | $7,270,000 | +99625.7% | 1,000,000 | 0.0% | 2.36% | +11.5% | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $6,288,989 | +62520.6% | 247,598 | 0.0% | 2.05% | -30.0% | |
| VOR | Vor Biopharma, Inc. | $5,781,660 | +80807.6% | 1,074,658 | 0.0% | 1.88% | -9.5% | |
| ACET | Adicet Bio, Inc. | $4,198,717 | +64327.1% | 728,944 | 0.0% | 1.37% | -28.0% | |
| ALDX | Aldeyra Therapeutics, Inc. | $3,920,702 | +142574.7% | 394,834 | 0.0% | 1.28% | +59.4% | |
| NNOX | Buy | Nano-X Imaging Ltd. | $1,833,152 | +126498.9% | 317,704 | +61.9% | 0.60% | +41.6% |
| SomaLogic, Inc. | $716,683 | +101557.2% | 281,052 | 0.0% | 0.23% | +13.7% | ||
| PHGE | BiomX Inc. | $650,688 | +163389.4% | 2,133,402 | 0.0% | 0.21% | +82.8% | |
| New | Apollomics, Inc. | $320,698 | – | 13,252 | +100.0% | 0.10% | – | |
| CLSD | Clearside Biomedical, Inc. | $176,414 | +92749.5% | 169,629 | 0.0% | 0.06% | +3.6% | |
| TCON | Tracon Pharmaceuticals, Inc. | $158,766 | +126912.8% | 84,003 | 0.0% | 0.05% | +44.4% | |
| SENS | Senseonics Holdings, Inc. | $38,781 | +69151.8% | 54,621 | 0.0% | 0.01% | -18.8% | |
| VTGN | New | VistaGen Therapeutics, Inc. | $23,755 | – | 190,494 | +100.0% | 0.01% | – |
| CBIO | Catalyst Biosciences, Inc. | $13,859 | +39497.1% | 66,951 | 0.0% | 0.01% | -50.0% | |
| GRAY | Exit | Graybug Vision, Inc. | $0 | – | -49,547 | -100.0% | -0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LEGEND BIOTECH CORPORATION | 9 | Q3 2023 | 25.6% |
| FATE THERAPEUTICS, INC. | 9 | Q3 2023 | 24.8% |
| PROTAGONIST THERAPEUTICS INC. | 9 | Q3 2023 | 21.0% |
| CVRX, INC. | 9 | Q3 2023 | 19.5% |
| MEIRAGTX HOLDINGS PLC | 9 | Q3 2023 | 13.9% |
| Arrowhead Pharmaceuticals, Inc. | 9 | Q3 2023 | 24.6% |
| PROCEPT BIOROBOTICS CORPORATION | 9 | Q3 2023 | 10.5% |
| CUE HEALTH, INC. | 9 | Q3 2023 | 8.5% |
| FUSION PHARMACEUTICALS INC. | 9 | Q3 2023 | 5.4% |
| POINT BIOPHARMA GLOBAL INC. | 9 | Q3 2023 | 2.8% |
View JOHNSON & JOHNSON's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Fusion Pharmaceuticals Inc. | January 27, 2023 | 3,670,516 | 8.2% |
| Protagonist Therapeutics, Inc | January 11, 2023 | 2,449,183 | 5.0% |
| MeiraGTx Holdings plc | November 14, 2022 | 6,641,064 | 13.7% |
| PhaseBio Pharmaceuticals Inc | February 01, 2022 | 1,607,044 | 3.3% |
| Provention Bio, Inc. | January 17, 2020 | 1,124,973 | 2.4% |
| ADURO BIOTECH, INC. | January 22, 2019 | 3,906,207 | 4.9% |
| Aldeyra Therapeutics, Inc. | January 22, 2019 | 1,050,292 | 4.0% |
| GI DYNAMICS, INC. | January 22, 2019 | 565,569 | 3.7% |
| MACROGENICS INC | January 22, 2019 | 1,923,077 | 4.6% |
| Merus N.V. | January 22, 2019 | ? | ? |
View JOHNSON & JOHNSON's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 8-K/A | 2024-04-16 |
| 8-K | 2024-04-16 |
| 3 | 2024-04-10 |
| SC 13G | 2024-04-10 |
| DFAN14A | 2024-04-05 |
| PX14A6G | 2024-03-27 |
| 144 | 2024-03-13 |
| 4 | 2024-03-13 |
| ARS | 2024-03-13 |
| DEF 14A | 2024-03-13 |
View JOHNSON & JOHNSON's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.